To explore the role of Aurora kinase B (AURKB) in HPV-induced cervical cancer and assess its potential as a therapeutic target.
Approach:
Mechanistic Insights: The article discusses how HPV oncogenes E6 and E7 influence AURKB activity, leading to genomic instability and tumor progression.
Therapeutic Evaluation: Preclinical studies on AURKB inhibitors like barasertib and AZD2811 are reviewed for their effects on tumor cell proliferation and treatment sensitivity.
Key Findings:
AURKB is overexpressed in cervical cancer and correlates with tumor stage and therapeutic resistance.
HPV E6 and E7 oncoproteins interact with AURKB, leading to increased genomic instability.
Pharmacological inhibition of AURKB has been shown to suppress tumor cell proliferation and enhance sensitivity to chemotherapy and radiotherapy.
Interpretation:
AURKB is implicated in the progression of cervical cancer, and its inhibition may represent a potential therapeutic strategy.
Limitations:
Clinical evaluation of AURKB inhibitors remains limited.
Further research is needed to establish the efficacy of AURKB-targeted therapies in clinical settings.
Conclusion:
The review highlights the potential of AURKB inhibition in precision oncology for HPV-driven cervical cancer.
